Oncology health professionals' attitudes toward treatment-focused genetic testing for women newly diagnosed with breast cancer.

@article{Burcher2013OncologyHP,
  title={Oncology health professionals' attitudes toward treatment-focused genetic testing for women newly diagnosed with breast cancer.},
  author={Stephanie Burcher and Bettina Meiser and Gillian Mitchell and Christobel M Saunders and Belinda Rahman and Kathy M Tucker and Kristine Barlow-Stewart and Kaaren J. Watts and Margaret Gleeson and Judy Kirk},
  journal={Personalized medicine},
  year={2013},
  volume={10 5},
  pages={
          431-440
        }
}
AIM This study explored the attitudes of oncology health professionals towards treatment-focused genetic testing (TFGT) for women newly diagnosed with breast cancer. MATERIALS & METHODS Members of several relevant medical organizations in Australia and New Zealand were invited via email to participate in an online survey. RESULTS A total of 149 respondents, including 40 surgeons, 46 oncologists and 63 breast care nurses, completed the online questionnaire. The majority of respondents… 

Tables from this paper

Health professionals’ evaluation of delivering treatment-focused genetic testing to women newly diagnosed with breast cancer

While costs of TFGT itself and the time and effort of staff involved were perceived barriers, it is expected that TFGT will become a routine part of standard clinical care for patients at high genetic risk in the near future.

Moving into the mainstream: healthcare professionals’ views of implementing treatment focussed genetic testing in breast cancer care

Genetics and non-genetics professionals’ perceptions of mainstreaming are influenced by their views of: their clinical roles and responsibilities, the impact of TFGT on their workload and the patient pathway and the perceived relevance of genetic testing for patient care in the short-term.

Communication about genetic testing and hereditary cancer management with breast and ovarian cancer patients

Patients received insufficient information to understand their future cancer risks and make informed decisions about managing hereditary cancer, and refinements to communication as genetic testing is integrated into mainstream oncology are guided.

Attitudes and training needs of oncologists and surgeons in mainstreaming breast cancer genetic counseling in a low‐to‐middle income Asian country

The attitudes, considerations, and self‐efficacy of oncologists, breast surgeons, and general surgeons in mainstreaming breast cancer genetic counseling in Malaysia are evaluated, highlighting the urgent need to train more nongenetics healthcare professionals in providing genetic counseling and testing in low‐to‐middle income countries.

Streamlined genetic education is effective in preparing women newly diagnosed with breast cancer for decision making about treatment-focused genetic testing: a randomized controlled noninferiority trial

A streamlined model of educating women newly diagnosed with breast cancer about TFGT seems to be a cost-effective way of delivering education while ensuring that women feel informed and supported in their decision making, thus freeing resources for other women to access TFGT.

Recommendations for the management of early breast cancer in women with an identified BRCA 1 or

  • Medicine
  • 2014
This guideline includes statements and recommendations based on available evidence about the management of early breast cancer in women with an identified BRCA1 or BRCA2 gene mutation or at high risk

Correction: The composition and capacity of the clinical genetics workforce in high-income countries: a scoping review

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

The composition and capacity of the clinical genetics workforce in high-income countries: a scoping review

There is currently a shortage of genetics providers and that there is a lack of consensus about the appropriate boundaries between the scopes of practice for genetics and nongenetics providers, and strategies that may be used to increase productivity and efficiency are pointed to.

Mainstreaming genetics and genomics: a systematic review of the barriers and facilitators for nurses and physicians in secondary and tertiary care

Nurses and physicians are largely underprepared to integrate genetic and genomic health information into routine clinical care, and the knowledge–practice gap could limit patients’ and families’ access to vital genetic information.

References

SHOWING 1-10 OF 26 REFERENCES

Getting to the point: what women newly diagnosed with breast cancer want to know about treatment-focused genetic testing.

This pilot study has provided timely initial evidence on the efficacy of a brief written resource in preparing women for decision making about treatment-focused genetic testing (TFGT) and will assist oncology nurses to make important genetic risk information available to women newly diagnosed with breast cancer at a stressful time.

BRCA testing of breast cancer patients: medical specialists' referral patterns, knowledge and attitudes to genetic testing.

A substantial (11-56%) proportion of medical specialists do not refer patients who meet current criteria for BRCA testing, and although questions on inheritance were less well answered, overall knowledge was good.

Are we being overly cautious? A qualitative inquiry into the experiences and perceptions of treatment-focused germline BRCA genetic testing amongst women recently diagnosed with breast cancer

It is concluded that an offer of TFGT is not perceived as ‘too much, too soon’ by relevant patients, and is viewed favourably by women newly diagnosed with breast cancer.

Utilization of BRCA1/BRCA2 Mutation Testing in Newly Diagnosed Breast Cancer Patients

Background: Among newly diagnosed breast cancer patients who are at risk for carrying a BRCA1 or BRCA2 mutation, knowledge of mutation status can influence local breast cancer treatment decisions.

Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda

The literature is reviewed on the rationale for genetic testing to aid with treatment decisions, the potential benefits of using mutation or risk status to tailor management, and the evidence regarding women's decision-making regarding treatment-focused genetic counselling and testing and the associated psychological impact.

Genetic counseling and clinical management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations: perspective of a surgical oncologist

An algorithm is designed for the management of women with a family history of breast cancer who are diagnosed with breast cancer and counseled to undergo prophylactic mastectomy which minimizes these lifelong problems.

Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.

Prophylactic mastectomy is associated with a substantial reduction in the incidence of subsequent breast cancer not only in women identified as being at high risk on the basis of a family history of breast cancer but also in known BRCA1 or BRCa2 mutation carriers.

Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.

Whether or not women diagnosed with breast cancer under the age of 40 would want to be offered information about genetic testing close to the time of their diagnosis is investigated and whether the health care professionals treating them support this idea is explored.

Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy

In conclusion, BRCA1/2 mutation carriers with breast cancer have similar survival whether treated with M or BCT, however, women undergoing BCT have an elevated risk of a second in-breast event that is significantly reduced in the presence of chemotherapy.